Royalty Pharma Recoups Pelacarsen Bet Despite Phase 3 Failure — Royalty Pharma plc

Event summary

Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet primary endpoint of reducing cardiovascular events in patients with elevated Lp(a).
Royalty Pharma's $500M funding agreement with Ionis structured to recoup investment despite pelacarsen failure, earning modest positive return.
Royalty Pharma retains 25% of Ionis' Spinraza royalties through 2027, increasing to 45% in 2028 on up to $1.5B in annual sales.
No milestone payments anticipated to Ionis; Royalty Pharma's royalty interest in Spinraza to revert to Ionis after $550M in payments.
Royalty Pharma reaffirms 2030 Portfolio Receipts target of $4.7B or more.

The big picture

Royalty Pharma's ability to structure protective agreements highlights its strategic edge in biopharmaceutical royalties. The pelacarsen failure underscores the high-risk nature of clinical trials, but Royalty Pharma's diversified portfolio and focus on stable royalties like Spinraza position it to weather such setbacks. The reaffirmation of the 2030 target suggests confidence in the broader portfolio's performance despite individual trial failures.

What we're watching

Royalty Portfolio Resilience: How Royalty Pharma's diversified portfolio will offset the pelacarsen setback and sustain growth toward the 2030 target.
Spinraza Royalty Dynamics: Whether the reversion of Spinraza royalties to Ionis will impact Royalty Pharma's long-term revenue streams.
Novartis' Pipeline Strategy: The pace at which Novartis will pivot from the pelacarsen failure to other cardiovascular disease candidates.